SCHEMBL4070974

SCHEMBL4070974

O=C(NCCCCC/C=C(\F)CO)Nc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.57
CCR2 P41597 1/20 0.47
RAB9A P51151 2/20 0.47
GOT1 P17174 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
POLB P06746 1/20 0.45
FAAH O00519 1/20 0.44
NAMPT P43490 2/20 0.43
CNR1 P21554 1/20 0.43
MCHR1 Q99705 1/20 0.43
KDM4E B2RXH2 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 1/20 0.42
EPHX1 P07099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4115662 1.00 EPHX2 (0.57) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4070978 1.00 EPHX2 (0.57) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4012335 0.88 EPHX2 (0.61) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4012063 0.88 EPHX2 (0.61) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4012061 0.88 EPHX2 (0.61) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4016209 0.87 EPHX2 (0.57) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4016204 0.87 EPHX2 (0.57) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4016211 0.87 EPHX2 (0.57) EPHX2CCR2RAB9AGOT1KMT2A
SCHEMBL4016701 0.85 MEN1 (0.55) EPHX2GOT1KMT2AMEN1NAMPT
SCHEMBL4016698 0.85 MEN1 (0.55) EPHX2GOT1KMT2AMEN1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247521-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION ARETE THERAPEUTICS, INC. 2009-10-01 US claimed
US-20090247521-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION ARETE THERAPEUTICS, INC. 2009-10-01 US disclosed
US-20090247521-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION ARETE THERAPEUTICS, INC. 2009-10-01 US disclosed
US-20090247521-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION ARETE THERAPEUTICS, INC. 2009-10-01 US disclosed
WO-2009086429-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS ARETE THERAPEUTICS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247521-A1 SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION EPHX1, ECE1, LIPG EPHX2 5/4885CCR2 2208/4885RAB9A 2783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.